Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer

Autor: David A. Fox, Bruce Carrington, Rachel Davis, Alex Vugler, John Robert Porter, Timothy John Norman, Benjamin P. Cossins, Boris Kroeplien, Fabien Claude Lecomte, David McMillan, Alastair D. G. Lawson, Alex B. Burgin, Tim Bourne, Stephen Edward Rapecki, Tom Ceska, O'connell James Philip, Alison Maloney, Tracy Arakaki
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Neutrophils
Science
medicine.medical_treatment
Anti-Inflammatory Agents
General Physics and Astronomy
Arthritis
Molecular Dynamics Simulation
Crystallography
X-Ray

General Biochemistry
Genetics and Molecular Biology

Cell Line
Mice
Structure-Activity Relationship
03 medical and health sciences
0302 clinical medicine
Mediator
In vivo
Drug Discovery
medicine
Animals
Protein Structure
Quaternary

lcsh:Science
Receptor
Multidisciplinary
Protein Stability
Tumor Necrosis Factor-alpha
Chemistry
Drug discovery
General Chemistry
medicine.disease
Arthritis
Experimental

Small molecule
Recombinant Proteins
Treatment Outcome
030104 developmental biology
Cytokine
Neutrophil Infiltration
Receptors
Tumor Necrosis Factor
Type I

Cancer research
lcsh:Q
Tumor necrosis factor alpha
Protein Multimerization
030217 neurology & neurosurgery
Signal Transduction
Zdroj: Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
ISSN: 2041-1723
Popis: Tumour necrosis factor (TNF) is a cytokine belonging to a family of trimeric proteins; it has been shown to be a key mediator in autoimmune diseases such as rheumatoid arthritis and Crohn’s disease. While TNF is the target of several successful biologic drugs, attempts to design small molecule therapies directed to this cytokine have not led to approved products. Here we report the discovery of potent small molecule inhibitors of TNF that stabilise an asymmetrical form of the soluble TNF trimer, compromising signalling and inhibiting the functions of TNF in vitro and in vivo. This discovery paves the way for a class of small molecule drugs capable of modulating TNF function by stabilising a naturally sampled, receptor-incompetent conformation of TNF. Furthermore, this approach may prove to be a more general mechanism for inhibiting protein–protein interactions.
Databáze: OpenAIRE